Alnylam Pharmaceuticals NASDAQ: ALNY is expanding its sales force and working to reach more physicians as it seeks to accelerate demand for AMVUTTRA in transthyretin amyloid cardiomyopathy, or ATTR-CM, executives said at the Jefferies Global Healthcare Conference in London.
CEO Yvonne Greenstreet said the company was pleased with the drug’s growth approximately 18 months into the launch, but not with the pace of demand. About one-third of targeted physicians have prescribed AMVUTTRA, and the company has reached 2,000 prescribers, she said.
Alnylam has expanded its field force by about 25% to deepen relationships with existing prescribers and reach new ones. Greenstreet said the immediate priority is converting those interactions into patient starts. The company plans to continue reporting its prescriber expansion metric.
Some cardiologists accustomed to prescribing pills may have concerns about administering an injectable treatment, Greenstreet said. Alnylam can help practices purchase and bill for AMVUTTRA or refer patients to alternative care sites, she said, adding that 90% of patients can access the drug within 10 miles of home.
Asked about the departure of Alnylam’s chief commercial officer, Greenstreet said the company remains committed to its field-force expansion strategy and is searching for a leader who can support AMVUTTRA’s next phase of growth and potential future launches.
Insurance Access and 340B Changes
CFO Jeff Poulton said approximately 99% of people in the U.S. have insurance policies that cover AMVUTTRA, and about 75% currently have first-line access. UnitedHealth and Aetna have placed the drug on non-preferred tiers in Medicare Advantage plans, according to the discussion.
Poulton said the two insurers represent about 10% and 5% of covered lives, respectively. He said Alnylam was not aware of additional major Medicare Advantage policy changes for 2027, although plans can review their policies annually. The company will seek to maintain first-line access by differentiating AMVUTTRA’s clinical profile, he said.
Executives also discussed a 2027 change to reimbursement for institutions purchasing drugs through the 340B program. Poulton said reimbursement will move from average sales price plus 6% to average sales price minus 28%, substantially changing the economics for those institutions.
Alnylam intends to offer contracts and discounts to keep purchases through the 340B channel economically viable, Poulton said. Alternatively, institutions could purchase AMVUTTRA outside that channel or send patients to other sites of care. Additional 340B discounts would pressure Alnylam’s net price, while purchases outside the channel would be more favorable for pricing, he said.
The overall impact remains uncertain because it depends on institutions’ purchasing decisions, Poulton said. Alnylam expects to finalize its contracting approach by mid-December and plans to provide guidance at its year-end results call in February, after gaining several weeks of experience with the new rule.
Nucresiran Trial Expanded
Chief Medical Officer Pushkal Garg said Alnylam has twice increased enrollment in TRITON-CM, its Phase 3 study of the next-generation TTR silencer nucresiran. The increases total 1,000 patients, bringing the planned study size to 2,250.
Garg said the changes were intended to account for declining background event rates as patients are diagnosed earlier and receive other treatments. The study is event-driven, and Alnylam continues to expect results and a potential market launch around 2030, he said.
The trial is also designed to include more patients earlier in their disease. Garg said findings from earlier studies gave the company confidence that TTR silencers can benefit those patients, including patients already treated with stabilizers. He described nucresiran as having greater silencing potency and less frequent dosing than AMVUTTRA.
About Alnylam Pharmaceuticals (NASDAQ:ALNY)
Alnylam Pharmaceuticals is a biopharmaceutical company focused on discovering, developing and commercializing medicines based on RNA interference (RNAi), a biological process that can reduce the production of specific disease-causing proteins. Founded in 2002 and headquartered in Cambridge, Massachusetts, the company helped advance RNAi from a scientific discovery into a therapeutic approach. Its marketed medicines include ONPATTRO (patisiran) and AMVUTTRA (vutrisiran) for hereditary transthyretin-mediated amyloidosis, GIVLAARI (givosiran) for acute hepatic porphyria, and OXLUMO (lumasiran) for primary hyperoxaluria type 1.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Alnylam Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alnylam Pharmaceuticals wasn't on the list.
While Alnylam Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.